NBTX
Nanobiotix S.A.
There isn't enough reported data to score NBTX yet.
NBTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NBTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NBTX PE Valuation
NBTX has no meaningful PE right now: it lost money over the past year.
NBTX Forward outlook
There aren't enough analyst estimates for NBTX to show an outlook.
NBTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$0.82 | +$1.05 |
| Q4 2023 | -$1.20 | +$0.62 |
| Q2 2023 | -$1.87 | -$0.50 |
| Q4 2022 | -$1.82 | -$0.32 |
NBTX lost $0.56 per share over the past year, a smaller loss than the year before.
NBTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $6.2M | -79% |
| Q2 2025 | $29.6M | +187% |
| Q2 2024 | $10.3M | +182% |
| Q4 2023 | $36.6M | +855% |
| Q2 2023 | $3.7M | +148% |
| Q4 2022 | $3.8M | +160% |
| Q2 2022 | $1.5M | +0.8% |
| Q4 2021 | $1.5M | +51% |
NBTX's revenue has slid since its 2023 peak: $6M last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -323% | -68 points |
| Q4 2025 | -195% | -191 points |
| Q2 2025 | 3% | +773 points |
| Q2 2024 | -255% | +1693 points |
| Q4 2023 | -4.3% | +1713 points |
| Q2 2023 | -770% | +1487 points |
| Q4 2022 | -604% | +1453 points |
| Q2 2022 | -1947% | -678 points |
NBTX's operating margin was −323% last quarter, down 319 points from the same quarter a year ago.
NBTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$25.5M | -$6M |
| Q4 2025 | -$18.2M | -$2.6M |
| Q2 2025 | -$19.5M | -$12.5M |
| Q4 2024 | -$15.6M | -394% |
| Q2 2024 | -$7M | +$12.5M |
| Q4 2023 | $5.3M | +$27.1M |
| Q2 2023 | -$19.5M | -$1.1K |
| Q4 2022 | -$21.8M | -$5.1M |
NBTX has burned cash in almost every quarter: −$79M over the past year, against −$43M the year before.
NBTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +1.5M shares |
| 1 year | +116% | +26.3M shares |
| 3 years | +227% | +33.9M shares |
NBTX has 49M diluted shares, up 116% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2024 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
NBTX Net Leverage
NBTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NBTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.4 | Neutral |
| Stochastic | 41.2 | Neutral |
NBTX's weekly RSI is 49 (neutral) and its Stochastic is 41 (neutral).
NBTX PE vs Healthcare Sector
NBTX has no meaningful PE right now: it lost money over the past year.
NBTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.5 | 13% above |
| 20 week MA | $34.6 | 6.8% below |
| 50 week MA | $32.0 | 0.7% above |
| 100 week MA | $20.0 | 61% above |
| 200 week MA | $12.9 | 150% above |
NBTX's trend is mixed: it's above four of its five weekly moving averages, and 150% above its 200-week average.
NBTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.0 | $17.2 | +1.5% |
| 2021 | $17.2 | $7.87 | -54% |
| 2022 | $7.87 | $4.00 | -49% |
| 2023 | $4.00 | $7.28 | +82% |
| 2024 | $7.28 | $3.00 | -59% |
| 2025 | $3.00 | $23.0 | +668% |
| 2026 YTD | $23.0 | $32.3 | +40% |
NBTX's yearly returns have swung widely, from +668% in 2025 to −59% in 2024. It's up 40% so far in 2026.